• By ICR Secretariat
  • Posted Wednesday, April 15, 2020

Early data on Gilead coronavirus drug raises hope, but answers few questions


Three dozen patients with COVID-19 given an experimental Gilead drug called remdesivir appeared to improve in the days following treatment, raising some hope the antiviral therapy could prove beneficial in larger and more rigorous studies that are currently ongoing.

The results are not from a clinical trial, but rather amassed from 53 people who received the drug through compassionate use programs designed to allow patients with few options early access to medicines still in development.